![Alan Tyndall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Alan Tyndall is the founder of Magenta Therapeutics, Inc. (2015).
He is currently a Professor-Emeritus at the University of Basel (since 1991) and serves as Secretary at the World Scleroderma Foundation.
Mr. Tyndall received his undergraduate degree from the University of Sydney in 1972.
Mr. Tyndall is also the founder of Iterata AG.
Actieve functies van Alan Tyndall
Bedrijven | Functie | Begin |
---|---|---|
University of Basel | Corporate Officer/Principal | 01-01-1991 |
World Scleroderma Foundation | Bedrijfssecretaris | - |
Iterata AG | Oprichter | - |
Eerdere bekende functies van Alan Tyndall
Bedrijven | Functie | Einde |
---|---|---|
MAGENTA THERAPEUTICS | Oprichter | - |
Opleiding van Alan Tyndall
The University of Sydney | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Magenta Therapeutics, Inc.
![]() Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
World Scleroderma Foundation | |
Iterata AG |